However, for patients with advanced NSCLC included in CheckMate 017 [24] and OAK [25] who received second-line immunotherapy compared with chemotherapy, the level of PD-L1 expression could not predict the efficacy. Here, CD274 is linked to non-small cell lung carcinoma.